Clinical trial · Observational
Quality of Life Among Survivors of Hodgkin Lymphoma
A Global Assessment of Medical Morbidities and Quality of Life Among Survivors of Hodgkin Lymphoma
NCT00598728CI-TRIAL-00021946completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to collect information on the long-term side effects of treatment for Hodgkin Lymphoma. We hope to study about 500-800 survivors of Hodgkin Lymphoma. We plan to use the findings from this study to better understand Hodgkin Lymphoma survivors' health and quality of life.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hodgkin's Disease | Hodgkin Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Quality of Life Questionaires | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- 1
- description
- Hodgkin lymphoma Survivors
- interventionNames
- Behavioral: Quality of Life Questionaires
Primary outcomes (1)
- measure
- To evaluate the prevalence of late medical complications among HL survivors
- timeFrame
- conclusion of study
Secondary outcomes (1)
- measure
- To study the effect of HL and its treatment on QOL among HL survivors.
- timeFrame
- conclusion of study
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Biopsy-proven HL Participation in IRB-approved protocols for the first-line treatment of HL between 1975-2000 (IRB #75-104, #75-103, #79-17, #81-103, #90-44, #91-69). * English speaking Exclusion Criteria: * None
References
Publications (0)
Data not yet available
No reference posted for this study.